Health Care · Pharmaceutical Preparations · NYSE · CIK 1724521 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $28.25Day +6.81%Mkt cap $3.6B1Y +199.6%Off 52W high −11.0%Vol (1Y) 61.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,102 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest10.0% of sh out |
| Days to cover12.9d |
| 13F net flow (QoQ)−0.26% |
| Top-10 13F concentration68.7% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$236.0M |
| Earnings (TTM)-$369.0M |
| ROE−63.3% |
| Net margin−142.9% |
| ROIC−68.4% |
| Debt / equity0.16× |
| Sales growth 3Y30.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+18.5% |
| 1Y+199.6% |
| 3Y+42.0% |
| 5Y−10.1% |
| Since incept. (ann.)+6.3% |
Total return through 2026-07-30 · series begins 2018-03-15. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)61.5% |
| Ann. volatility (3Y)62.3% |
| Sharpe (1Y)2.08 |
| Sharpe (3Y)0.50 |
| Max drawdown (1Y)−27.8% |
| Max drawdown (3Y)−70.2% |
| Beta (3Y vs SPY)1.46 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 31.4M | $679M | 25.07% | +0.0% |
| BlackRock, Inc. | 15.2M | $329M | 12.15% | +1.5% |
| WELLINGTON MANAGEMENT GROUP LLP | 6.1M | $132M | 4.86% | +17.5% |
| STATE STREET CORP | 5.4M | $117M | 4.32% | +18.3% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5.0M | $109M | 4.01% | −3.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.3M | $92M | 3.41% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9M | $83M | 3.08% | new |
| Woodline Partners LP | 3.8M | $82M | 3.01% | +0.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | −$1.02 | — | $17.0M | −39.3% |
| 2025-12-31 | 2026-02-25 | — | — | $33.0M | +26.9% |
| 2025-09-30 | 2025-10-28 | −$1.27 | — | $26.0M | −45.8% |
| 2025-06-30 | 2025-08-06 | $0.00 | — | $160.0M | +310.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
